The Drive to Discover. The Experience to Deliver.
INCYTE
Learn More
Incyte 2012 Annual Report
to Stockholders
to Stockholders
is a biopharmaceutical company focused on discovering, developing and
commercializing proprietary small molecule drugs for oncology
and inflammation.
News
Incyte Reports First-Quarter 2013 Financial Results; Updates Shareholders on Key Clinical Programs
Incyte Reports 2012 Fourth-Quarter and Full Year Financial Results; Provides 2013 Financial Guidance; Updates Shareholders on Key Clinical Programs
New Data for Jakafi® (ruxolitinib) Presented at the 2012 American Society of Hematology Annual Meeting
Jakafi® (ruxolitinib)
IncyteCARES
Connecting to Access, Reimbursement, Education and Support
To learn more, click here
To learn more, click here